21-037 - AALL1821 - A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: openAALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Treatment for Pediatric Oncology- B-ALL
Description
To compare rate of minimal residual disease (MRD) negative second remission after up to two cycles of Reinduction with blinatumomab vs. blinatumomab/nivolumab in Group 1 patients aged ≥ 1 to < 31 years old with first relapse of CD19+ B-ALL. To compare EFSPI (EFS post-Induction) between Consolidation with blinatumomab vs. blinatumomab/nivolumab in Group 3 patients aged ≥ 1 to <31 years old with first relapse of CD19+ B-ALL.
Sponsors
This trial is sponsored by Children's Oncology Group.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
Sub Investigators
![Ilonze chibuzo]()
View ProfileChibuzo Ilonze, M.D., M.P.H.Pediatric Hematologist/OncologistAssistant Professor of Pediatric Hematology/Oncology
